New trials, publications, preprints and grants on this target, month by month.
Trial
Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
18 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Frequent FLT3 and IDH co-mutations in acute myeloid leukemia with mutated NPM1, NUP98 rearrangement, and KMT2A partial tandem duplication but not rearrangement: potential for combined targeted therapy.
5 Nov 2026· Haematologica· PUBMED
Publication
Complex and Cryptic KMT2A::MLLT10 Rearrangements in Acute Myeloid Leukemia Resolved by Optical Genome Mapping.
1 Nov 2026· Genes, chromosomes & cancer· PUBMED
Publication
Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial.
1 Nov 2026· The Lancet. Haematology· PUBMED
Publication
Targeting menin dependency in acute leukemias: the role of revumenib in NPM1-mutated and KMT2A/NUP98-rearranged disease.
29 Oct 2026· Future oncology (London, England)· PUBMED
Publication
Genome-Wide and Multi-Omics Analysis Identified DNA-Interacting Circular RNA circFOXK2 as MLL1 Regulator for Histone H3K4 Methylation in Pancreatic Ductal Adenocarcinoma.
29 Oct 2026· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publication
Pre-transplant immunotherapy and MRD dynamics affect post-transplant prognosis in KMT2A-rearranged B-ALL patients.
28 Oct 2026· Bone marrow transplantation· PUBMED
Publication
Comparative analysis of KMT2A fusions in human models of acute myeloid leukemia.
24 Oct 2026· Experimental hematology· PUBMED
Publication
LIN28B is essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia.
22 Oct 2026· Blood· PUBMED
Trial
S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation
20 Oct 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
The NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab.
15 Oct 2026· Blood· PUBMED
Trial
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
14 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Three-Way Chromosomal Translocation Involving KMT2A::MLLT3 in AML: A Case Report and Genomic Characterization.
12 Oct 2026· Cytogenetic and genome research· PUBMED
Trial
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
1 Oct 2026· PHASE2 · RECRUITING· CTGOV
Trial
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
28 Sept 2026· PHASE1 · RECRUITING· CTGOV
Publication
Targeting tomorrow: Evaluation of novel agents for infants with KMT2A-rearranged acute lymphoblastic leukaemia.
22 Sept 2026· Blood reviews· PUBMED
Publication
Acute Myeloid Leukemia With KMT2A Amplification: A TP53-Alteration-Enriched Subgroup Associated With Chromoanagenesis and Poor Prognosis.
17 Sept 2026· Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc· PUBMED
Publication
Cuplike nuclei and bimodal CD34 expression in adult KMT2A-rearranged pro-B acute lymphoblastic leukemia.
10 Sept 2026· Blood· PUBMED
Publication
Measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in acute myeloid leukemia.
3 Sept 2026· Haematologica· PUBMED
Trial
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
2 Sept 2026· PHASE1 · RECRUITING· CTGOV
Publication
Spatial Lineage Divergence at Diagnosis in a Pediatric KMT2A-Rearranged Leukemia Presenting with Concurrent AML and B-LBL.
27 Aug 2026· Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society· PUBMED
Publication
Clinicomolecular features and clonal evolution of KMT2A-PTD AML: prognostic impact of concurrent FLT3-ITD under 2022 ELN risk stratification.
25 Aug 2026· Blood cancer journal· PUBMED
Publication
Successful treatment of relapsed KMT2A rearranged AML with central nervous system involvement using revumenib in combination with venetoclax and azacitidine: A case report.
24 Aug 2026· Therapeutic advances in hematology· PUBMED
Publication
Modeling KRAS mutations in KMT2A::MLLT3 acute myeloid leukemia promotes leukemic progression and transcriptional rewiring.
18 Aug 2026· Leukemia· PUBMED
Publication
[KMT2A-rearranged acute lymphoblastic leukemia with lineage switch following relapse: a case report and literature review].
14 Aug 2026· Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi· PUBMED
Publication
A novel KMT2A::AFF1-derived fusion circRNA regulates mitochondrial metabolism in t(4;11) B-cell acute lymphoblastic leukemia.
13 Aug 2026· Haematologica· PUBMED
Publication
A Case of Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) with Immunophenotypic Features Suggestive of B/Myeloid Mixed-Phenotype Acute Leukemia (MPAL), Harboring Multiple KMT2A Gene Amplifications.
11 Aug 2026· International journal of molecular sciences· PUBMED
Publication
Fusion-subtype and single-cell analyses refine the interpretation of HDAC8 dependency in KMT2A-rearranged AML.
7 Aug 2026· Leukemia· PUBMED
Publication
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models.
6 Aug 2026· Blood· PUBMED